Literature DB >> 20205264

Clinical analysis of PMS2: mutation detection and avoidance of pseudogenes.

Cecily P Vaughn1, Jorge Robles, Jeffrey J Swensen, Christine E Miller, Elaine Lyon, Rong Mao, Pinar Bayrak-Toydemir, Wade S Samowitz.   

Abstract

Germline mutation detection in PMS2, one of four mismatch repair genes associated with Lynch syndrome, is greatly complicated by the presence of numerous pseudogenes. We used a modification of a long-range PCR method to evaluate PMS2 in 145 clinical samples. This modification avoids potential interference from the pseudogene PMS2CL by utilizing a long-range product spanning exons 11-15, with the forward primer anchored in exon 10, an exon not shared by PMS2CL. Large deletions were identified by MLPA. Pathogenic PMS2 mutations were identified in 22 of 59 patients whose tumors showed isolated loss of PMS2 by immunohistochemistry (IHC), the IHC profile most commonly associated with a germline PMS2 mutation. Three additional patients with pathogenic mutations were identified from 53 samples without IHC data. Thirty-seven percent of the identified mutations were large deletions encompassing one or more exons. In 27 patients whose tumors showed absence of either another protein or combination of proteins, no pathogenic mutations were identified. We conclude that modified long-range PCR can be used to preferentially amplify the PMS2 gene and avoid pseudogene interference, thus providing a clinically useful germline analysis of PMS2. Our data also support the use of IHC screening to direct germline testing of PMS2. (c) 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20205264     DOI: 10.1002/humu.21230

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  30 in total

1.  Identification of individuals at risk for Lynch syndrome using targeted evaluations and genetic testing: National Society of Genetic Counselors and the Collaborative Group of the Americas on Inherited Colorectal Cancer joint practice guideline.

Authors:  Scott M Weissman; Randall Burt; James Church; Steve Erdman; Heather Hampel; Spring Holter; Kory Jasperson; Matt F Kalady; Joy Larsen Haidle; Henry T Lynch; Selvi Palaniappan; Paul E Wise; Leigha Senter
Journal:  J Genet Couns       Date:  2011-12-14       Impact factor: 2.537

2.  Predictive genetic testing of a bone marrow recipient-ethical issues involving unexpected results, gender issues, test accuracy, and implications for the donor.

Authors:  A Sexton; L Rawlings; M Jenkins; I Winship
Journal:  J Genet Couns       Date:  2013-08-30       Impact factor: 2.537

3.  Exome Sequencing Identifies Biallelic MSH3 Germline Mutations as a Recessive Subtype of Colorectal Adenomatous Polyposis.

Authors:  Ronja Adam; Isabel Spier; Bixiao Zhao; Michael Kloth; Jonathan Marquez; Inga Hinrichsen; Jutta Kirfel; Aylar Tafazzoli; Sukanya Horpaopan; Siegfried Uhlhaas; Dietlinde Stienen; Nicolaus Friedrichs; Janine Altmüller; Andreas Laner; Stefanie Holzapfel; Sophia Peters; Katrin Kayser; Holger Thiele; Elke Holinski-Feder; Giancarlo Marra; Glen Kristiansen; Markus M Nöthen; Reinhard Büttner; Gabriela Möslein; Regina C Betz; Angela Brieger; Richard P Lifton; Stefan Aretz
Journal:  Am J Hum Genet       Date:  2016-07-28       Impact factor: 11.025

4.  Elucidating the clinical significance of two PMS2 missense variants coexisting in a family fulfilling hereditary cancer criteria.

Authors:  Maribel González-Acosta; Jesús Del Valle; Matilde Navarro; Bryony A Thompson; Sílvia Iglesias; Xavier Sanjuan; María José Paúles; Natàlia Padilla; Anna Fernández; Raquel Cuesta; Àlex Teulé; Guido Plotz; Juan Cadiñanos; Xavier de la Cruz; Francesc Balaguer; Conxi Lázaro; Marta Pineda; Gabriel Capellá
Journal:  Fam Cancer       Date:  2017-10       Impact factor: 2.375

Review 5.  The changing landscape of Lynch syndrome due to PMS2 mutations.

Authors:  J Blount; A Prakash
Journal:  Clin Genet       Date:  2018-03-15       Impact factor: 4.438

6.  Absence of PMS2 mutations in colon-CFR participants whose colorectal cancers demonstrate unexplained loss of MLH1 expression.

Authors:  M Clendenning; F A Macrae; M D Walsh; R J Walters; S N Thibodeau; S R Gunawardena; J D Potter; R W Haile; S Gallinger; J L Hopper; M A Jenkins; C Rosty; J P Young; D D Buchanan
Journal:  Clin Genet       Date:  2012-09-27       Impact factor: 4.438

7.  Screening for germline mutations in mismatch repair genes in patients with Lynch syndrome by next generation sequencing.

Authors:  Barbara Luísa Soares; Ayslan Castro Brant; Renan Gomes; Tatiane Pastor; Naye Balzan Schneider; Ândrea Ribeiro-Dos-Santos; Paulo Pimentel de Assumpção; Maria Isabel W Achatz; Patrícia Ashton-Prolla; Miguel Angelo Martins Moreira
Journal:  Fam Cancer       Date:  2018-07       Impact factor: 2.375

8.  Screening for Lynch syndrome in young Saudi colorectal cancer patients using microsatellite instability testing and next generation sequencing.

Authors:  Masood Alqahtani; Caitlin Edwards; Natasha Buzzacott; Karen Carpenter; Khalid Alsaleh; Abdulmalik Alsheikh; Waleed Abozeed; Miral Mashhour; Afnan Almousa; Yousef Housawi; Shareefa Al Hawwaj; Barry Iacopetta
Journal:  Fam Cancer       Date:  2018-04       Impact factor: 2.375

9.  Detection of large scale 3' deletions in the PMS2 gene amongst Colon-CFR participants: have we been missing anything?

Authors:  Mark Clendenning; Michael D Walsh; Judith Balmana Gelpi; Stephen N Thibodeau; Noralane Lindor; John D Potter; Polly Newcomb; Loic LeMarchand; Robert Haile; Steve Gallinger; John L Hopper; Mark A Jenkins; Christophe Rosty; Joanne P Young; Daniel D Buchanan
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

10.  Somatic mosaicism and double somatic hits can lead to MSI colorectal tumors.

Authors:  Isabelle Sourrouille; Florence Coulet; Jeremie H Lefevre; Chrystelle Colas; Mélanie Eyries; Magali Svrcek; Armelle Bardier-Dupas; Yann Parc; Florent Soubrier
Journal:  Fam Cancer       Date:  2013-03       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.